Evaluating statin use after brain hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SATURN trial investigates whether patients who experience spontaneous lobar intracerebral hemorrhage (ICH) should continue or discontinue their statin medications. This multi-center, randomized clinical trial will enroll 1,456 patients within 7 days of their ICH event, assessing the impact of statin therapy on the recurrence of ICH and major adverse cerebro-/cardio-vascular events over a 24-month follow-up period. Additionally, a subset of participants will undergo MRI scans to evaluate the effects of statin therapy on cerebral small vessel disease markers. The study will also consider the influence of the APOE genotype on treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 50 years.
2. Spontaneous lobar ICH confirmed by CT or MRI scan
3. Patient was taking a statin drug at the onset of the qualifying/index ICH
4. Randomization can be carried out within 7 days of the onset of the qualifying ICH
5. Patient or legally authorized representative, after consultation with the statin prescriber, agrees to be randomized to statin continuation (restart) vs. discontinuation

Exclusion Criteria:

1. Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct.
2. History of recent myocardial infarction (attributed to coronary artery disease) or unstable angina within the previous 3 months
3. Diabetic patients with history of myocardial infarction or coronary revascularization
4. History of familial hypercholesterolemia
5. Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors
6. Known diagnosis of severe dementia
7. Inability to obtain informed consent
8. Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits/assessments.
9. Life expectancy of less than 24 months due to co-morbid terminal conditions.
10. Pre-morbid mRS \>3
11. ICH score \>3 upon presentation.
12. Contraindications to continuation/resumption of statin therapy, such as significant elevations of serum creatinine kinase and/or liver transaminases, and rhabdomyolysis
13. Woman of childbearing potential
14. Concurrent participation in another research protocol for investigation of experimental therapy.
15. Indication that withdrawal of care will be implemented for the qualifying ICH.

Where it's running

• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Magdy Selim, MD, PhD
• Email: mselim@bidmc.harvard.edu
• Phone: 617-632-8917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries

  Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.

  Recruiting Columbia University · Miami, Florida and 8 other locations · NCT07917728

• Chinese multicenter group studies spontaneous intracerebral hemorrhage in adults

  This study tests how a large group of adults with spontaneous intracerebral hemorrhage (and a healthy control group) progress over time to understand outcomes and determinants of recovery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07833410

• Rapid Evacuation and Access of Cerebral Hemorrhage Registry: observing minimally invasive surgery outcomes

  This registry collection tests how minimally invasive brain-bleed procedures work in real patients with acute spontaneous intracerebral hemorrhage.

  Recruiting Emory University · Atlanta, Georgia · NCT07651631

• Single triple-combination blood pressure pill after intracerebral hemorrhage

  This trial tests whether a single pill combining amlodipine, valsartan, and hydrochlorothiazide helps adults who recently had an intracerebral hemorrhage control their blood pressure.

  Recruiting The University of Hong Kong · Hong Kong, Hong Kong and 3 other locations · NCT07458880

• Vitamin D treatment after intracerebral hemorrhage

  This will try giving higher-dose vitamin D to adults within 96 hours of an intracerebral hemorrhage to see if it helps clear the bleed faster and is safe.

  Recruiting The University of Hong Kong · Hong Kong · NCT07458815

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.